Press Release - February 3, 2015
Heidelberg, Germany, February 03, 2015 – Affimed N.V. (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present at the 17th BIO CEO & Investor Conference, to be held February 9-10, 2015, as well as at the 2015 Leerink Partners Global Healthcare Conference to be held February 11-12, 2015. Both conferences will be at the Waldorf Astoria New York.
17th Annual BIO CEO & Investor Conference
Dr. Hoess’ presentation will take place Tuesday, February 10, 2:30 p.m. (ET).
To access a simultaneous webcast of Mr. Hoess’ presentation online, log on to http://www.veracast.com/webcasts/bio/ceoinvestor2015/08220587762.cfm or go to the Webcast section on the Affimed website.
2015 Leerink Partners Global Healthcare Conference
Dr. Hoess’ presentation will take place Thursday, February 12, 10:20 a.m. (ET).
To access a simultaneous webcast of Mr. Hoess’ presentation online, log on to http://leerink.metameetings.com/confbook/healthcare15/directlink?ticker=AFMD or go to the Webcast section on the Affimed website.
A replay of the both webcasts will be available from Affimed’s website for 30 days following the respective conference. Mr. Hoess’ presentations will be available for download in PDF format immediately following the respective conference presentation.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Affimed N.V.
Adi Hoess, CEO
Phone: +49 6221 65307-0
E-Mail: email hidden; JavaScript is required
Anca Alexandru or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or +49 163 613 3359
E-Mail: email hidden; JavaScript is required